However, according to global cancer data from 2020, about 90% of cancer incidence is caused by solid tumors, while hematologic malignancies (non-solid tumors) account for only about 10%.
Moreover, as an innovative cell therapy, CAR-T is considered a high-risk drug in clinical trials. Cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and other side effects are common with CAR-T cell therapy, and once they occur, there is a risk of life-threatening complications.
